Bleeding in patients with activated partial thromboplastin time inhibitors.
We present a case in which an activated partial thromboplastin time (aPTT) inhibitor may have significantly contributed to prolonged bleeding in a patient and review five similar cases. The possibility of an aPTT inhibitor should be considered in the evaluation of patients with unexplained prolongation of PTT and PT. Such patients may develop significant bleeding even in the absence of other hematologic abnormalities.
D001777:Blood Coagulation; D001778:Blood Coagulation Disorders / Q000150:complications*; D001987:Bronchiectasis / Q000097:blood / Q000150:complications; D006417:Hematuria / Q000150:complications; D006470:Hemorrhage / Q000097:blood*; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000097:blood; D008297:Male; D008875:Middle Aged; D010314:Partial Thromboplastin Time; D011470:Prostatic Hyperplasia / Q000097:blood / Q000150:complications; D011517:Prothrombin Time